ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 63 citations in OpenAlex.
- Burkitt lymphoma: current understanding, unmet needs, and research directions.Blood advances · 2026Review
- Article
- PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.Leukemia · 2026Article
- Overcoming chemotherapy resistance in diffuse large B-cell lymphoma using multifunctional nanocarriers: current advances and clinical challenges.Discover nano · 2026Review
- T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2Nature communications · 2026Article
- A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.Cell reports. Medicine · 2025Article
- PDX models for functional precision oncology and discovery science.Nature reviews. Cancer · 2025Review
- A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma.Cancers · 2024Article
- Development of patient-derived lymphomoids with preserved tumor architecture for lymphoma therapy screening.Nature communications · 2024Article
- Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor.Cell reports. Medicine · 2024Article
- Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature.Acta haematologica · 2024Review
- Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease.Nature communications · 2023Article
- Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.Journal of hematology & oncology · 2023Review
- Article
- Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies.Life science alliance · 2023Article
- Patient-derived xenograft models in cancer therapy: technologies and applications.Signal transduction and targeted therapy · 2023Review
- Mouse models of diffuse large B cell lymphoma.Frontiers in immunology · 2023Review
- Modeling the crosstalk between malignant B cells and their microenvironment in B-cell lymphomas: challenges and opportunities.Frontiers in immunology · 2023Review
- Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy.Frontiers in immunology · 2023Review
- Individualized therapy based on the combination of mini-PDX and NGS for a patient with metastatic AFP-producing and HER-2 amplified gastric cancer.Oncology letters · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 3 institutions in 1 country.
Leo ZhangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Krystle NomieDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hui ZhangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Taylor BellDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lan PhamDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sabah KadriDivison of Genomic and Molecular Pathology, Department of Pathology, The University of Chicago, Chicago, Illinois.
Jeremy SegalDivison of Genomic and Molecular Pathology, Department of Pathology, The University of Chicago, Chicago, Illinois.
Shaoying LiDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shouhao ZhouDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David SantosDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shawana RichardDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shruti SharmaDivison of Genomic and Molecular Pathology, Department of Pathology, The University of Chicago, Chicago, Illinois.
Wendy ChenDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Onyekachukwu OriabureDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yang LiuDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shengjian HuangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hui GuoDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zhihong ChenDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wenjing TaoDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Carrie LiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jack WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bingliang FangDepartment of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jacqueline WangDepartment of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lei LiDepartment of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maria BadilloDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Makhdum AhmedDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Selvi ThirumurthiDepartment of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Steven Y HuangDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yiping ShaoDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Laura LamDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Qing YiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Y Lynn WangDivison of Genomic and Molecular Pathology, Department of Pathology, The University of Chicago, Chicago, Illinois.
Michael WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. miwang@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USUniversity of Chicago · USCleveland Clinic Lerner College of Medicine · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MOvercoming Primary Ibrutinib Resistance in Mantle Cell Lymphoma Using Patient-Derived Models and Molecular ProfilingR21CA202104 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, MICHAEL · 2016 to 2017
$383kNCI NIH HHS P30 CA016672NCI NIH HHS R21 CA202104
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenineAgammaglobulinaemia Tyrosine KinaseAnimalsBurkitt LymphomaDisease Models, AnimalDrug DiscoveryDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansLymphoma, B-Cell, Marginal ZoneLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellMicePhosphatidylinositol 3-KinasesPiperidinesAdenineAgammaglobulinaemia Tyrosine KinaseBtk protein, mouseibrutinibPhosphatidylinositol 3-KinasesPiperidinesProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.